Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Summary

This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria for dose hold or dose reduction

Timeline

Start

2017-03-31

Primary completion

2018-07-24

Completion

2019-02-15

Drugs

Indications